Debt-to-equity of Inmune Bio, Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Inmune Bio, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Inmune Bio, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 28%, a 41% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Inmune Bio, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 28% -19% -41% 30 Sep 2025
Q2 2025 30% -18% -38% 30 Jun 2025
Q1 2025 33% -13% -28% 31 Mar 2025
Q4 2024 40% +1% +1.6% 31 Dec 2024
Q3 2024 47% +10% +28% 30 Sep 2024
Q2 2024 48% +13% +39% 30 Jun 2024
Q1 2024 46% +15% +46% 31 Mar 2024
Q4 2023 40% +11% +37% 31 Dec 2023
Q3 2023 37% +10% +40% 30 Sep 2023
Q2 2023 35% +11% +44% 30 Jun 2023
Q1 2023 31% +5% +20% 31 Mar 2023
Q4 2022 29% +8% +36% 31 Dec 2022
Q3 2022 26% +9% +50% 30 Sep 2022
Q2 2022 24% +12% +93% 30 Jun 2022
Q1 2022 26% +22% +503% 31 Mar 2022
Q4 2021 21% +16% +332% 31 Dec 2021
Q3 2021 18% +13% +275% 30 Sep 2021
Q2 2021 12% +8% +176% 30 Jun 2021
Q1 2021 4% +1% +21% 31 Mar 2021
Q4 2020 5% +2% +61% 31 Dec 2020
Q3 2020 5% +1% +43% 30 Sep 2020
Q2 2020 5% 30 Jun 2020
Q1 2020 4% 31 Mar 2020
Q4 2019 3% 31 Dec 2019
Q3 2019 3% 30 Sep 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.